Cancer name Glioblastoma
Cancer Type GBM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment IFN-β
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature HLA-E
Official Symbol HLA-E
Mode of action PROT_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description The transcripts encoding typical (HLA-A, -B, -C) and atypical MHC proteins (HLA-E, -Fand -G), as well as proteins of the immuno-proteasome (TAP1,PSMB8 and PSMB9)were increased upon stimulation with IFN-β. Moreover, genes encoding chemokines, toll-like recep-tors or death receptor ligands were upregulated.
PMID 26441059
Title Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells.